Licoisoflavone A
Based on 2 publication(s) in Google Scholar
Licoisoflavone A is an orally active isoflavone. Licoisoflavone A inhibits proliferation, induces apoptosis, and causes G1/S phase arrest in colorectal cancer (CRC) cells. Licoisoflavone A inhibits the CDK2-Cyclin E1 axis. Licoisoflavone A inhibits lipid peroxidation with an IC50 of 7.2 μM. Licoisoflavone A shows a dose-dependent inhibition effect on SARS-CoV-2 infection. Licoisoflavone A exhibits significant anti-tumor efficacy in mice bearing CT26 cell subcutaneous xenografts. Licoisoflavone A can be used for the study of colorectal cancer and SARS-CoV-2 infection.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- Purity : 99.53%
- CAS No.: 66056-19-7
- 화학식: C20H18O6
- 분자량:354.35
-
보관:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
용액&용해도
- Protocol
- 순도&문서
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Licoisoflavone A
More
Biological Activity
제품 설명
In Vitro
Licoisoflavone A (0-100 μM) inhibits RNA-dependent RNA polymerase (RdRp) and cAMP-specific 3’,5’-cyclic phosphodiesterase 4 (PDE4) with IC50 values of 47.31 μM and 1.77 μM, respectively[1].
Licoisoflavone A (5 μM, 2 days) significantly reduces the cross-sectional area of Ang II-induced hypertrophic H9c2 cells by approximately 46%[2].
Licoisoflavone A (15 μM, 48 h) upregulates Sirt3 expression and reduces MnSOD acetylation at K68 in PE-induced neonatal rat cardiomyocytes[2].
Licoisoflavone A (15 μM, 48 h) decreases relative ANF and BNP levels in Phenylephrine (PE) (HY-B0769)-induced hypertrophic cardiac cells, but this effect is blocked when co-treated with Sirt3 inhibitor 3-TYP (HY-108331)[2].
Licoisoflavone A ( 6.25-25 μM, 48 h) significantly inhibits proliferation, induces apoptosis, and causes G1/S phase arrest in HCT116 and SW480 colorectal cancer (CRC) cells[4].
Licoisoflavone A (6.25-25 μM, 48 h) downregulates CDK2, Cyclin E1, and phosphorylated Rb (p-Rb) while upregulating p27 in HCT116 and SW480 cells, inhibiting the CDK2-Cyclin E1 axis[4].
Licoisoflavone A (1-1000000 nM, 3 days) dose-dependently inhibits viability of 5 patient-derived CRC organoids (CRCOs) with IC50 values ranging from 7.02 to 82.98 μM, and shows lower toxicity to normal colorectal organoids (CNOs)[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:PE-induced hypertrophic cardiac cells
-
Concentration:15 μM
-
Incubation Time:48 h
-
Result:Decreased relative ANF and BNP levels in PE-induced hypertrophic cardiac cells, but this effect is blocked when co-treated with Sirt3 inhibitor 3-TYP.
-
Cell Line:HCT116 and SW480 colorectal cancer (CRC) cells
-
Concentration:6.25, 12.5, 25 μM
-
Incubation Time:48 h
-
Result:CausesdG1/S phase arrest in HCT116 and SW480 colorectal cancer (CRC) cells.
-
Cell Line:HCT116 and SW480 colorectal cancer (CRC) cells
-
Concentration:6.25, 12.5, 25 μM
-
Incubation Time:48 h
-
Result:Induced apoptosis in HCT116 and SW480 colorectal cancer (CRC) cells.
-
Cell Line:HCT116 and SW480 colorectal cancer (CRC) cells
-
Concentration:6.25, 12.5, 25 μM
-
Incubation Time:48 h
-
Result:Downregulated CDK2, Cyclin E1, and phosphorylated Rb (p-Rb).
Upregulated p27.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:CT26.WT cells (106 in 100 μL) were subcutaneously inoculated into the right axillary region of 6-week-old male BALB/c SPF mice[4].
-
Dosage:25, 50 mg/kg
-
Administration:p.o. daily for 2 weeks
-
Result:Achieved dose-dependent tumor growth inhibition in BALB/c mice bearing CT26 cell xenografts, with reduced tumor weight and volume at 25 mg/kg and 50 mg/kg doses.
Showed no significant toxicity, with no abnormal changes in liver and spleen histopathology and serum ALT/AST levels.
Reduced the expression of CDK2 and Cyclin E1 in tumor tissues, while increased p27 expression.
Inhibited phosphorylation of Rb in tumor tissues.
- How to Select the Route of Administration for Mammals
- EdU Incorporation Assay (Click Chemistry-Based DNA Synthesis Measurement)
- Research Protocol for Infectious Diseases
- Detection of Apoptosis
- TUNEL staining for apoptotic DNA fragmentation
- Flow cytometric DNA-content cell-cycle staining
- Annexin V plus membrane-impermeant dye apoptosis staining
- BrdU Incorporation Assay
- Apoptosis Solutions
- Protocol for Cell Cycle
- Ferroptosis Solutions
- Cell Viability Determination by MTT Colorimetric Assay
Chemical Information
-
CAS No. 66056-19-7
-
Appearance Solid
-
분자량 354.35
-
화학식 C20H18O6
-
Color Light yellow to yellow
-
SMILES
O=C1C(C2=C(C(C/C=C(C)/C)=C(O)C=C2)O)=COC3=CC(O)=CC(O)=C13
-
Structure Classification
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (2)
-
Journal Impact Factor
-
Most Recent
-
Food Chem
Effects of sun drying combined with baking processes on the flavor quality of Chongqing Tuocha raw tea. [Abstract]2025 Dec 30:497:146992. PMID: 41285060 -
Food Chem
Flavonoid-mediated metabolic underpinning quality variation in red bud-sport pear mutants. [Abstract]2025 Oct 15:489:144992. PMID: 40466530
용액&용해도
In Vitro:
DMSO : 100 mg/mL (282.21 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (7.06 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (7.06 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
순도&문서
-
Data Sheet (280 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Xu H, et al. Bioactive compounds from Huashi Baidu decoction possess both antiviral and anti-inflammatory effects against COVID-19. Proc Natl Acad Sci U S A. 2023 May 2;120(18):e2301775120. [Content Brief]
[2]. Guo R, et al. High content screening identifies licoisoflavone A as a bioactive compound of Tongmaiyangxin Pills to restrain cardiomyocyte hypertrophy via activating Sirt3. Phytomedicine. 2020 Mar;68:153171. [Content Brief]
[4]. Cui J, et al. Licoisoflavone A inhibits colorectal cancer cell proliferation through targeting CDK2-Cyclin E1 axis-mediated cell cycle transition. Biochem Pharmacol. 2025 Oct;240:117124. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.8221 mL | 14.1103 mL | 28.2207 mL | 70.5517 mL |
| 5 mM | 0.5644 mL | 2.8221 mL | 5.6441 mL | 14.1103 mL | |
| 10 mM | 0.2822 mL | 1.4110 mL | 2.8221 mL | 7.0552 mL | |
| 15 mM | 0.1881 mL | 0.9407 mL | 1.8814 mL | 4.7034 mL | |
| 20 mM | 0.1411 mL | 0.7055 mL | 1.4110 mL | 3.5276 mL | |
| 25 mM | 0.1129 mL | 0.5644 mL | 1.1288 mL | 2.8221 mL | |
| 30 mM | 0.0941 mL | 0.4703 mL | 0.9407 mL | 2.3517 mL | |
| 40 mM | 0.0706 mL | 0.3528 mL | 0.7055 mL | 1.7638 mL | |
| 50 mM | 0.0564 mL | 0.2822 mL | 0.5644 mL | 1.4110 mL | |
| 60 mM | 0.0470 mL | 0.2352 mL | 0.4703 mL | 1.1759 mL | |
| 80 mM | 0.0353 mL | 0.1764 mL | 0.3528 mL | 0.8819 mL | |
| 100 mM | 0.0282 mL | 0.1411 mL | 0.2822 mL | 0.7055 mL |
Licoisoflavone A Related Classifications
HY-N3389 Related Classifications
Powered by Bioz